Early Diagnosis, Disease Stage and Prognosis in Wild-Type Transthyretin Amyloid Cardiomyopathy: The DIAMOND Study
ESC Heart Failure · 01.02.2025 · 12 (1) · 379-388
DOI: 10.1002/ehf2.15091 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift ESC Heart Failure, online erschienen am 20.09.2024. Verfasst von Giacomo Tini und 49 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Early Diagnosis, Cardiomyopathies. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Aims
Disease staging and prognostic scoring in wild-type transthyretin-related cardiac amyloidosis (ATTRwt-CA) can be captured by two systems (NAC and Columbia scores). However, uncertainty remains as epidemiology of the disease is evolving rapidly. We evaluated features associated with staging systems across ATTRwt-CA patients from different diagnostic pathways, and their association with prognosis.
Methods
We performed an analysis on DIAMOND patients with available data to evaluate NAC and Columbia score. DIAMOND was a retrospective study from 17 Italian referral centres for CA, enrolling 1281 patients diagnosed between 2016 and 2021, and aimed at describing characteristics of pathways leading to ATTRwt-CA diagnosis. Of the original cohort, 811 patients were included in this analysis. Each patient had NAC and Columbia score calculated. Patients were grouped according to NAC and Columbia scoring classes. We described characteristics of patients according to staging classes and diagnostic pathways at diagnosis. Prevalence of early diagnoses, defined as NAC Ia, NYHA class I, no use of diuretics, no history of heart failure (HF) hospitalizations nor of atrial fibrillation prior to diagnosis, was investigated. Finally, prognostic variables were tested alone and grouped as NAC or Columbia scores in Cox univariate and multivariate regression analyses. Prognosis was investigated as all-cause mortality, in the whole population and dividing patients in HF versus other diagnostic pathways.
Results
Only 1% of the study population had an early ATTRwt-CA diagnosis. Distribution of prognostic variables and of NAC and Columbia classes was heterogeneous across diagnostic pathways. The prevalence of NAC III and Columbia III was higher in the HF diagnostic pathway, but all NAC and Columbia classes were present in all pathways. Both NAC and Columbia scores were associated with all-cause mortality at univariate Cox regression analysis in the whole population, in patients from the HF diagnostic pathway and in those from other pathways. At multivariate analysis, Columbia score remained significantly associated with the outcome, together with age at diagnosis, left ventricular ejection fraction and maximal wall thickness.
Conclusions
In this contemporary nationwide cohort, an ATTRwt-CA early diagnosis was very rare. Disease staging with NAC and Columbia scoring systems determined classes of patients with heterogeneous features. Both scores were significantly associated with mortality, but other variables also had prognostic significance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy.
- Department of Molecular Medicine, University of Pavia, Pavia, Italy.
- Amyloidosis Research and Treatment Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy.
- Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy.
- Cardiology Unit, St. Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
ORCID-Profile: Marco Canepa
Förderung
- Pfizer
Zitieren
APA
Tini, G., Musumeci, B., Milani, P., Zampieri, M., Caponetti, A. G., Fabris, F., Foli, A., Argirò, A., Mazzoni, C., Gagliardi, C., Longhi, S., Saturi, G., Vergaro, G., Aimo, A., De Fazio, L., Varrà, G. G., Serenelli, M., Fabbri, G., De Michieli, L., …, & Canepa, M. (2025). Early Diagnosis, Disease Stage and Prognosis in Wild-Type Transthyretin Amyloid Cardiomyopathy: The DIAMOND Study. ESC Heart Failure, 12(1), 379-388. https://doi.org/10.1002/ehf2.15091
Vancouver
Tini G, Musumeci B, Milani P, Zampieri M, Caponetti AG, Fabris F, et al. Early Diagnosis, Disease Stage and Prognosis in Wild-Type Transthyretin Amyloid Cardiomyopathy: The DIAMOND Study. ESC Heart Failure. 2025;12(1):379-388. doi:10.1002/ehf2.15091
BibTeX
@article{Tini2025,
author = {Tini, Giacomo and Musumeci, Beatrice and Milani, Paolo and Zampieri, Mattia and Caponetti, Angelo Giuseppe and Fabris, Francesca and Foli, Andrea and Argirò, Alessia and Mazzoni, Carlotta and Gagliardi, Christian and Longhi, Simone and Saturi, Giulia and Vergaro, Giuseppe and Aimo, Alberto and De Fazio, Ludovica and Varrà, Guerino Giuseppe and Serenelli, Matteo and Fabbri, Gioele and De Michieli, Laura and Palmiero, Giuseppe and Ciliberti, Giuseppe and Carigi, Samuela and Zanoletti, Margherita and Mandoli, Giulia Elena and Lucchi, Giulia Ricci and Rella, Valeria and Monti, Enrico and Gardini, Elisa and Bartolotti, Michela and Crotti, Lia and Merli, Elisa and Mussinelli, Roberta and Vianello, Pier Filippo and Cameli, Matteo and Marzo, Francesca and Guerra, Federico and Limongelli, Giuseppe and Cipriani, Alberto and Perlini, Stefano and Obici, Laura and Perfetto, Federico and Barbato, Emanuele and Porto, Italo and Sinagra, Gianfranco and Merlo, Marco and Emdin, Michele and Biagini, Elena and Cappelli, Francesco and Palladini, Giovanni and Canepa, Marco},
title = {Early Diagnosis, Disease Stage and Prognosis in Wild-Type Transthyretin Amyloid Cardiomyopathy: The DIAMOND Study},
journal = {ESC Heart Failure},
year = {2025},
volume = {12},
number = {1},
pages = {379--388},
doi = {10.1002/ehf2.15091}
}
EUVIMED